Results 101 to 110 of about 18,162 (243)

Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity

European Journal of Medical Research, 2010
Background in HIV-infected patients with HCV-related chronic hepatitis, liver impairment and drug toxicity may substantially reduce the number of possible therapeutic options.
Ortu F, Weimer LE, Floridia M, Manconi PE   +3 more
doaj   +1 more source

Improvement of neuropsychological performances and reduction of immune-activation markers after probiotic supplementation and change of life-style in an HIV positive male: targeting the microbiota to act on gut-brain axis [PDF]

, 2017
The gut-brain axis is widely in uenced by the intestinal microbiota and dysbiosis is consequently associated with a large dysregulation of its functions. Probiotic supplementation, reducing the harmful effects of dysbiosis, has shown positive effects not
Bianchi, Luigi, Cavallari, EUGENIO NELSON, Ceccarelli, Giancarlo, Corano Scheri, Giuseppe, D'Ettorre, Gabriella, Gabriella Di Girolamo,, Martiangela, Fratino, Vassalini, Paolo, Vullo, Vincenzo   +8 more
core  

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial [PDF]

, 2017
Pedro Cahn, Richard Kaplan, Paul E. Sax, Kathleen Squires, Jean‐Michel Molina, Anchalee Avihingsanon, Winai Ratanasuwan, Evelin Rojas, Mohammed Rassool, Mark Bloch, Linos Vandekerckhove, Peter Ruane, Yazdan Yazdanpanah, Christine Katlama, Xia Xu, Anthony Rodgers, Lilly East, Larissa Wenning, Sandy Rawlins, Brenda Homony, Peter Sklar, Bach‐Yen Nguyen, Randi Y. Leavitt, Hedy Teppler, PE Cahn, Isabel Cassetti, Marcelo H. Losso, MT Bloch, N Roth, James McMahon, Robert J. Moore, D.P. Smith, Nathan Clumeck, Linos Vanderkerckhove, B Vandercam, Michel Moutschen, Jean-Guy Baril, Brian Conway, Fiona Smaill, GHR Smith, Anita Rachlis, Sharon Walmsley, Carlos Enrique Tene Pérez, Marcelo Wolff, M. Lasso, CE Chahin, JD Velez, Otto Sussmann, Jacques Reynes, Christine Katlama, Yazdan Yazdanpanah, Samuel Ferret, J Durant, C Duvivier, Isabelle Poizot‐Martin, F. Ajana, JK Rockstroh, G Faetkanheuer, S Esser, Hans Jaeger, Olaf Degen, Markus Bickel, J. R. Bogner, Keikawus Arastéh, H Hartl, Albrecht Stoehr, EM Rojas, Eduardo Arathoon, LD Gonzalez, Christian R. Mejía, Eduardo Shahar, Dianna Turner, Idan Levy, Zev Sthoeger, Hila Elinav, Andrea Gori, Antonella d’Arminio Monforte, Giampaolo Perri, Adriano Lazzarin, G Rizzardini, Andrea Antinori, Benedetto Maurizio Celesia, F Maggiolo, TS Chow, CKC Lee, Iskandar Azwa, Mohammad Mustafa, Martin Oyanguren, RA Castillo, L. Hercilla, Carmenchu Echiverri, Fernando Maltêz, JG Saraiva da Cunha, Isabel Neves, Eugénio Teófilo, Rosário Serrão, Ф. И. Нагимова, И. М. Хаертынова, Elena Orlova‐Morozova, Evgeny Voronin   +99 more
openalex   +1 more source

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 583-586, March 2026.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA

Фармакоэкономика, 2015
The purpose of the work performed was assessment of cost efficiency of Raltegravir within the schemes of antiretroviral therapy as compared to the schemes on the basis of drugs from the group of protease inhibitors with adult patients with Type 1 HIV ...
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov   +4 more
doaj   +1 more source

Risk factors for raltegravir resistance development in clinical practice [PDF]

, 2012
Isabelle Malet, Slim Fourati, Laurence Morand‐Joubert, Philippe Flandre, Marc Wirden, S. Haïm-Boukobza, Sophie Sayon, Theresa Pattery, A. Simon, Christine Katlama, Pierre Marie Girard, Vincent Cálvez, Anne‐Geneviève Marcelin   +12 more
openalex   +1 more source

Assessing the contribution of UGT isoforms on raltegravir drug disposition through PBPK modeling

, 2022
Fernanda de Lima Moreira, Maria-Martha-de-Barros Tarozzo, Glauco Henrique Balthazar Nardotto, José-Carlos-Saraiva Gonçalves, Stephan Schmidt, Natália Valadares de Moraes   +5 more
openalex   +1 more source

Analysis of Transmitted Resistance to Raltegravir and Selective Pressure among HIV-1-Infected Patients on a Failing HAART in São Paulo, Brazil [PDF]

, 2012
We studied the presence of primary resistance to raltegravir (RAL), natural polymorphisms, and selection pressure on HIV-1 integrase. We found a high frequency of integrase polymorphisms related to the resistance to RAL and sequence stability.
Azevedo, R. G., Diaz, R. S., Komninakis, S. V., Mantovani, N. P., Rabelato, J. T., Sanabani, S.   +5 more
core   +2 more sources

Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors

Frontiers in Microbiology, 2019
More than 10 million people worldwide are infected with the retrovirus human T-cell lymphotropic virus type 1 (HTLV-1). Infection phenotypes can range from asymptomatic to severe adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy ...
Michał S. Barski, Jordan J. Minnell, Goedele N. Maertens   +2 more
doaj   +1 more source

Raltegravir: The First HIV Type 1 Integrase Inhibitor [PDF]

, 2009
Charles B. Hicks, Roy M. Gulick
openalex   +1 more source